MONTREAL (CANADA) – August 18, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, announces the presentation of preclinical data at the 2022 Congress of the European Respiratory Society (ERS), to be held in Barcelona, Spain and online.
Abstract: “INV-101, a cannabinoid receptor-1 inverse agonist, reduces fibrosis in a bleomycin mouse model of IPF”
Presenter: Glenn D. Crater, MD, FCCP, Chief Medical Officer, Inversago Pharma
Thematic Poster Session 23 (TP-23): “Promising new approaches in idiopathic interstitial pneumonias”
Date and Time: Monday, Sept. 5, 2022, 8:30-9:30am (CET)
To register for ERS International Congress 2022, please visit ersnet.org.
About Inversago Pharma
Located in Montreal, Inversago Pharma is a privately owned Canadian biotech company at clinical stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally acting CB1 inverse agonists. Inversago aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy (DN), Non-Alcoholic Steatohepatitis (NASH), complications from obesity, Hypertriglyceridemia (HTG), Type 1 Diabetes (T1D) and Prader-Willi Syndrome (PWS), as well as fibrotic indications like Progressive Fibrosis-Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF).
– 30 –
François Ravenelle, PhD
Chief Executive Officer
Inversago Pharma Inc.